vs

Side-by-side financial comparison of ASP Isotopes Inc. (ASPI) and Alpha Teknova, Inc. (TKNO). Click either name above to swap in a different company.

ASP Isotopes Inc. is the larger business by last-quarter revenue ($16.7M vs $10.0M, roughly 1.7× Alpha Teknova, Inc.). On growth, ASP Isotopes Inc. posted the faster year-over-year revenue change (1295.7% vs 7.8%). Alpha Teknova, Inc. produced more free cash flow last quarter ($-810.0K vs $-47.4M).

ASP Isotopes Inc. is a specialty materials firm focused on developing and producing high-purity custom isotopes. Its products serve key sectors including nuclear medicine, targeted cancer therapies, advanced energy, and industrial research, with customers across North America, Europe and Asia Pacific.

Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.

ASPI vs TKNO — Head-to-Head

Bigger by revenue
ASPI
ASPI
1.7× larger
ASPI
$16.7M
$10.0M
TKNO
Growing faster (revenue YoY)
ASPI
ASPI
+1287.9% gap
ASPI
1295.7%
7.8%
TKNO
More free cash flow
TKNO
TKNO
$46.6M more FCF
TKNO
$-810.0K
$-47.4M
ASPI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASPI
ASPI
TKNO
TKNO
Revenue
$16.7M
$10.0M
Net Profit
$-4.8M
Gross Margin
12.5%
32.5%
Operating Margin
-46.2%
Net Margin
-47.7%
Revenue YoY
1295.7%
7.8%
Net Profit YoY
-586.8%
16.8%
EPS (diluted)
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPI
ASPI
TKNO
TKNO
Q4 25
$16.7M
$10.0M
Q3 25
$4.9M
$10.5M
Q2 25
$10.3M
Q1 25
$9.8M
Q4 24
$9.3M
Q3 24
$9.6M
Q2 24
$9.6M
Q1 24
$9.3M
Net Profit
ASPI
ASPI
TKNO
TKNO
Q4 25
$-4.8M
Q3 25
$-12.9M
$-4.3M
Q2 25
$-3.6M
Q1 25
$-4.6M
Q4 24
$-5.7M
Q3 24
$-7.6M
Q2 24
$-5.4M
Q1 24
$-8.1M
Gross Margin
ASPI
ASPI
TKNO
TKNO
Q4 25
12.5%
32.5%
Q3 25
8.7%
30.7%
Q2 25
38.7%
Q1 25
30.7%
Q4 24
23.0%
Q3 24
0.9%
Q2 24
29.2%
Q1 24
23.8%
Operating Margin
ASPI
ASPI
TKNO
TKNO
Q4 25
-46.2%
Q3 25
-306.1%
-38.4%
Q2 25
-32.9%
Q1 25
-50.7%
Q4 24
-60.7%
Q3 24
-77.6%
Q2 24
-53.0%
Q1 24
-86.0%
Net Margin
ASPI
ASPI
TKNO
TKNO
Q4 25
-47.7%
Q3 25
-263.7%
-41.0%
Q2 25
-34.7%
Q1 25
-47.4%
Q4 24
-61.7%
Q3 24
-79.0%
Q2 24
-55.8%
Q1 24
-87.2%
EPS (diluted)
ASPI
ASPI
TKNO
TKNO
Q4 25
$-0.08
Q3 25
$-0.15
$-0.08
Q2 25
$-0.07
Q1 25
$-0.09
Q4 24
$-0.09
Q3 24
$-0.15
Q2 24
$-0.13
Q1 24
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPI
ASPI
TKNO
TKNO
Cash + ST InvestmentsLiquidity on hand
$333.3M
$21.3M
Total DebtLower is stronger
$14.4M
$13.1M
Stockholders' EquityBook value
$204.2M
$68.8M
Total Assets
$498.0M
$103.6M
Debt / EquityLower = less leverage
0.07×
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPI
ASPI
TKNO
TKNO
Q4 25
$333.3M
$21.3M
Q3 25
$113.9M
$22.1M
Q2 25
$24.0M
Q1 25
$26.3M
Q4 24
$30.4M
Q3 24
$31.7M
Q2 24
$18.6M
Q1 24
$21.6M
Total Debt
ASPI
ASPI
TKNO
TKNO
Q4 25
$14.4M
$13.1M
Q3 25
$13.9M
$13.1M
Q2 25
$13.0M
Q1 25
$13.0M
Q4 24
$9.4M
Q3 24
$10.9M
Q2 24
$12.3M
Q1 24
$13.2M
Stockholders' Equity
ASPI
ASPI
TKNO
TKNO
Q4 25
$204.2M
$68.8M
Q3 25
$74.1M
$72.7M
Q2 25
$76.1M
Q1 25
$78.6M
Q4 24
$82.4M
Q3 24
$87.3M
Q2 24
$78.9M
Q1 24
$83.4M
Total Assets
ASPI
ASPI
TKNO
TKNO
Q4 25
$498.0M
$103.6M
Q3 25
$225.9M
$107.6M
Q2 25
$110.5M
Q1 25
$114.0M
Q4 24
$118.8M
Q3 24
$124.1M
Q2 24
$115.4M
Q1 24
$120.8M
Debt / Equity
ASPI
ASPI
TKNO
TKNO
Q4 25
0.07×
0.19×
Q3 25
0.19×
0.18×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.11×
Q3 24
0.12×
Q2 24
0.16×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPI
ASPI
TKNO
TKNO
Operating Cash FlowLast quarter
$-37.8M
$-462.0K
Free Cash FlowOCF − Capex
$-47.4M
$-810.0K
FCF MarginFCF / Revenue
-284.7%
-8.1%
Capex IntensityCapex / Revenue
57.9%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-9.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPI
ASPI
TKNO
TKNO
Q4 25
$-37.8M
$-462.0K
Q3 25
$-8.9M
$-2.0M
Q2 25
$-2.1M
Q1 25
$-4.1M
Q4 24
$-936.0K
Q3 24
$-2.1M
Q2 24
$-2.8M
Q1 24
$-6.6M
Free Cash Flow
ASPI
ASPI
TKNO
TKNO
Q4 25
$-47.4M
$-810.0K
Q3 25
$-12.0M
$-2.4M
Q2 25
$-2.3M
Q1 25
$-4.3M
Q4 24
$-1.5M
Q3 24
$-2.4M
Q2 24
$-3.0M
Q1 24
$-6.7M
FCF Margin
ASPI
ASPI
TKNO
TKNO
Q4 25
-284.7%
-8.1%
Q3 25
-245.5%
-22.6%
Q2 25
-22.4%
Q1 25
-44.0%
Q4 24
-16.2%
Q3 24
-25.0%
Q2 24
-30.7%
Q1 24
-71.8%
Capex Intensity
ASPI
ASPI
TKNO
TKNO
Q4 25
57.9%
3.5%
Q3 25
64.4%
3.7%
Q2 25
2.0%
Q1 25
2.1%
Q4 24
6.1%
Q3 24
3.5%
Q2 24
1.2%
Q1 24
1.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASPI
ASPI

Segment breakdown not available.

TKNO
TKNO

Lab Essentials$6.8M68%
Clinical Solutions$2.7M27%
Other$435.0K4%

Related Comparisons